Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From David Wallace
The US Court of Appeals for the Federal Circuit has upheld a series of inter partes review decisions from 2017 in which three Humira patents were found invalid by the Patent Trial and Appeal Board within the US Patent and Trademark Office.
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.
Samsung Bioepis and partner AffaMed Therapeutics have received an approval from the Chinese authorities to conduct a Phase III study for their eculizumab biosimilar rival to Soliris at Chinese sites. Meanwhile, Samsung Bioepis has also just completed a global Phase III trial for its ranibizumab version of Lucentis.
December brought price rises for the UK generics market that included imipramine prices as much as doubling and a leap of more than two-thirds in the average price of frovatriptan tablets.
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.